Figure 1. Eligibility, Randomization, and Follow-up in the ACTIV-4a Trial of P2Y12 Inhibitors in Non–Critically Ill Patients Hospitalized for COVID-19.

ACTIV-4a indicates Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 Acute.

^aRandomization was stratified by hospital site and severity of illness.